Hypertriglyceridemia
Summary
Definition
Anamnesis y examen
Principales factores de diagnóstico
- eruptive xanthomas
- lipemia retinalis
Otros factores de diagnóstico
- increased BMI/waist circumference
- lipodystrophy
- features of coronary artery disease
- claudication
- neurologic features
- recurrent abdominal pain
Factores de riesgo
- family history of hyperlipidemia
- high saturated fat diet
- high carbohydrate or high glycemic index diet
- excessive alcohol consumption
- family or personal history of overweight/obesity
- family or personal history of diabetes
- insulin resistance
- liver disease
- renal disease
- HIV infection
- use of certain drugs
- Cushing syndrome
- inflammatory/immune disorders
- organ transplant
- hypothyroidism
- pregnancy
Pruebas diagnósticas
Primeras pruebas diagnósticas para solicitar
- triglyceride level
Pruebas diagnósticas que deben considerarse
- apolipoprotein B
- fasting plasma glucose
- BUN, creatinine
- urinary albumin/protein
- serum albumin
- thyroid-stimulating hormone
- liver function tests
- C-reactive protein
Algoritmo de tratamiento
chylomicronemia
moderate HTG (fasting TG ≥150 mg/dL [≥1.7 mmol/L] or nonfasting TG ≥175 mg/dL [≥2.0 mmol/L] and TG <500 mg/dL [<5.6 mmol/L])
severe HTG (fasting TG ≥500 mg/dL [≥5.6 mmol/L] especially fasting TG ≥1000 mg/dL [≥11.3 mmol/L])
Colaboradores
Autores
Robert A. Hegele, MD, FRCPC, Cert Endo, FACP, FAHA
Jacob J. Wolfe Distinguished Medical Research Chair
Martha Blackburn Chair in Cardiovascular Research
Distinguished University Professor of Medicine and Biochemistry
University of Western Ontario
London
Ontario
Canada
Divulgaciones
RAH reports consulting fees from Akcea/Ionis, Amgen, HLS Therapeutics, Medison, Novartis, Pfizer, Regeneron, Sanofi and Ultragenyx. RAH is an author of references cited in this topic.
Agradecimientos
Dr Robert A. Hegele would like to gratefully acknowledge Dr David Alexander Leaf, the previous contributor to this topic.
Divulgaciones
DAL declares that he has no competing interests.
Revisores por pares
Vinaya Simha, MBBS, MD
Associate Professor
Mayo Clinic
Rochester
MN
Divulgaciones
VS declares that he has no competing interests.
Agradecimiento de los revisores por pares
Los temas de BMJ Best Practice se actualizan de forma continua de acuerdo con los desarrollos en la evidencia y en las guías. Los revisores por pares listados aquí han revisado el contenido al menos una vez durante la historia del tema.
Divulgaciones
Las afiliaciones y divulgaciones de los revisores por pares se refieren al momento de la revisión.
Referencias
Artículos principales
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2019 Jun 18;139(25):e1082-143.Texto completo Resumen
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020 Jan 1;41(1):111-88.Texto completo Resumen
Patel SB, Wyne KL, Afreen S, et al. American Association of Clinical Endocrinology clinical practice guideline on pharmacologic management of adults with dyslipidemia. Endocr Pract. 2025 Feb;31(2):236-62.Texto completo Resumen
Artículos de referencia
Una lista completa de las fuentes a las que se hace referencia en este tema está disponible para los usuarios con acceso a todo BMJ Best Practice.
Diferenciales
- Diabetes
- Lipodystrophies
- Liver disease
Más DiferencialesGuías de práctica clínica
- 2025 AACE clinical practice guidelines on the pharmacologic management of adults with dyslipidemia
- 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias
Más Guías de práctica clínicaFolletos para el paciente
High cholesterol
Más Folletos para el paciente
Log in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer